Altai Protocol Library
Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions
New Reference: Alectinib for ALK-Positive Advanced NSCLC
The ALEX study demonstrated that alectinib numerically prolongs overall survival compared to crizotinib in patients with untreated ALK-positive non-small cell lung cancer. Alectini
New Drug: Imlunestrant for ESR1-Mutated Advanced Breast Cancer
In patients with ESR1 mutations, imlunestrant significantly improved progression-free survival compared to standard therapy. Imlunestrant–abemaciclib further improved progression
New Indication: Amivantamab-Lazertinib for First Line Advanced EGFR-Mutated NSCLC
The MARIPOSA trial demonstrated that amivantamab-lazertinib significantly improved overall survival compared to osimertinib in EGFR-mutated advanced NSCLC in 1st line setting, with
New Protocol: Belantamab Mafodotin with Bortezomib/Dexamethasone for R/R Myeloma
Global, randomised, open-label, phase 3 trial [DREAMM-7] Relapsed or refractory multiple myeloma after at least one line of therapy Belantamab-Bortezomib-dexamethasone (BVd) (n=243
New Drug: Telisotuzumab vedotin for cMET Amplified NSCLC
Phase 2, non-randomized, multicenter study (LUMINOSITY) Previously treated c-Met overexpressing NSQ EGFR wildtype advanced NSCLC (≤2 prior lines, ≤1 chemo) Telisotuzumab vedoti
New Drug: Penpulimab with Platinum – Gemcitabine in Advanced Nasopharyngeal Carcinoma
Global, multicenter, randomized, double-blind, phase 3 trial (AK105-304) Previously untreated recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) Penpulimab + gemcitabine/ci
New REference: Talazoparib and Enzalutamide for HRR-Deficient Prostate Cancer
Randomised, placebo-controlled, phase 3 trial [TALAPRO-2] Metastatic castration-resistant prostate cancer with HRR-deficiency Talazoparib+enzalutamide (n=200) vs enzalutamide+plac
New Reference: Advanced Pancreatic Cancer Protocols
Randomized, open-label, phase II/III trial [GENERATE, JCOG1611] Metastatic or recurrent pancreatic cancer mFOLFIRINOX (n=175) vs S-IROX (n=176) vs nab-paclitaxel gemcitabine (n=176
New Protocol: Brentuximab – ECADD Chemo for Hodgkin Lymphoma
Prospective, multicenter, single-arm, phase II cohort study [HD21 trial, NCT02661503] Older patients with advanced-stage classic Hodgkin lymphoma aged 61-75 years 4-6 cycles of PET
Our Solutions
Articles
Computerized Chemotherapy Order Entry
Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …
Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.